Clinical study on adefovir and lamivudine in treatment of chronic type B hepatitis patients with lamivudine medicine endurance
10.3760/cma.j.issn.1673-4904.2010.04.008
- VernacularTitle:阿德福韦酯联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究
- Author:
Baojian ZHU
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Drug resistance;
Lamivudine;
Adefovir dipivoxil
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(4):22-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the curative effect and the security of lamivudine (LM) and adefovir (AD) in the treatment of chronic type B hepatitis (CHB) patients with lamivudine medicine endurance. Methods The random-control method was used. Sixty-four CHB patients with LM endurance were randomized into treatment group (32 cases) and control group (32 cases). The patients in treatment group took LM 100 mg/d+AD 10 mg/d,and the patients in control group used AD 10 mg/d only. All of the patients were treated for 52 weeks. When treated for 24 weeks and 52 weeks, the HBV DNA transfer ratio, the HBeAg transfer ratio, the, HBeAg serology transfer ratio, the ALT restoration ratio, AD security and AD endurance rate in the 52th week were observed. Results The HBV DNA transfer ratio, the HBeAg transfer ratio, the HBeAg serology transfer ratio and the ALT restoration ratio in treatment group after 52 weeks' treatment were 81%(26/32),47% (15/32), 38% (12/32) and 94%(30/32). And those in control group were 53% (17/32), 22% (7/32), 12% (4/32) and 69% (22/32). There were significant differences between two groups (P < 0.05). No serious side effect was found in the course of treatment. Conclusion AD combined with LM has good curative effects in the virology, serology and biochemical aspect of LM endurance patients with lower medicine resistance and good security.
